<DOC>
	<DOCNO>NCT03074305</DOCNO>
	<brief_summary>The aim study compare angiographic outcome follow revascularization use drug-eluting balloon ( DEB ) versus 2nd generation drug-eluting stent ( DES ) treatment Bioresorbable Vascular Scaffold Restenosis .</brief_summary>
	<brief_title>DEB Versus 2nd Generation DES Patients With In-Scaffold Restenosis Bioresorbable Vascular Scaffold</brief_title>
	<detailed_description>The bioresorbable vascular scaffold ( BRS ) emerge new therapeutic option percutaneous coronary intervention coronary artery disease . Although 2nd generation drug-eluting stent ( DES ) enhance efficacy safety DES , However , along widespread use new generation DES clinical condition , include high-risk patient complicate lesion profile , ISR continue major concern , even era new generation DES . In regard , concept BRS introduce show promising result . Nevertheless , previous report show even BRS free restenosis , lead target lesion revascularization 7.4 % 3-year follow . Currently , previous research comparedsafety efficacy treatment option ISR lesion show similar clinical outcome follow 2 representative option , namely , drug-eluting balloon drug-eluting stent . In regard , current European Society Cardiology/European Association Cardiothoracic Surgery ( ESC/EACTS ) guideline recommend drug-eluting balloon ( DEB ) 2nd generation DES class IA recommendation treatment BMS DES-ISR . However , previous report evaluate ISR metallic stent , evidence treatment option BRS ISR . Therefore , Smart Angioplasty Research Team : Safety Efficacy Drug-Eluting Balloon versus 2nd Generation Drug-Eluting Stent Treatment In-Bioresorbable Vascular Scaffold Restenosis ( SMART-BRS-ISR ) trial randomly allocate patient BRS ISR DEB 2nd generation DES compare safety efficacy treatment option .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<criteria>Subject age 1985 year old Patients BRS ISR present angina symptom objective sign inducible myocardial ischemia ( one following ) 1 . Visual stenosis ≥50 % ISR segment typical angina symptom ( CCS class ≥II ) positive noninvasive stress test 2 . ISR lesion fractional flow reserve ( FFR ) ≤0.80 3 . Visual stenosis ≥70 % ISR segment ( absence 2 component ) Patients BRS ISR treat DEB angioplasty second generation DES implantation Cardiogenic shock ( Killip class IV ) already presentation completion culprit PCI Intolerance Aspirin , Clopidogrel , Plasugrel , Ticagrelor , Heparin , Bivaluridin , Everolimus , Zotarolimus Patients active bleed history gastrointestinal genitourinary major bleed within 3month Chronic kidney disease ( serum creatinine ≥2.0mg/dL estimate glomerular filtration rate &lt; 30ml/min ) Known true anaphylaxis contrast medium ( allergic reaction anaphylactic shock ) Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . Insegment edge restenosis without definite involvement previous BRS edge Unwillingness inability comply procedure describe protocol .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>In-bioresorbable vascular scaffold restenosis</keyword>
	<keyword>drug-eluting stent</keyword>
	<keyword>drug-eluting balloon</keyword>
	<keyword>bioresorbable scaffold</keyword>
</DOC>